New Monoclonal Antibody Nebokitug Shows Promise for Rare Liver Disease PSC

A Phase 2 clinical trial has shown that the new monoclonal antibody, nebokitug, is safe and potentially effective in treating Primary Sclerosing Cholangitis (PSC), a rare liver disease. Published in the American Journal of Gastroenterology, the study offers encouraging news for patients with limited treatment options.

• Nebokitug is a new monoclonal antibody for Primary Sclerosing Cholangitis (PSC).
• Phase 2 trial found nebokitug to be safe and well-tolerated in patients.
• The antibody showed potential efficacy by reducing liver fibrosis and inflammation.
• PSC is a rare, chronic liver disease with no effective treatments besides transplant.
• Nebokitug works by blocking the CCL24 protein, which contributes to liver damage.
• Results pave the way for a crucial Phase 3 study to further evaluate the drug.

Read the full story on Quick Digest.